| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $899K | -19.7% | -14.0% |
| SG&A Expense | $1.1M | -21.0% | -42.7% |
| Operating Income | -$2.0M | +20.4% | +32.8% |
| Net Income | -$2.1M | +27.5% | +22.2% |
| EPS (Basic) | -$0.19 | +44.1% | +62.7% |
| EPS (Diluted) | -$0.19 | +44.1% | +62.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5K | -99.4% | -97.0% |
| Current Assets | $508K | -66.5% | +39.6% |
| Total Assets | $1.4M | -46.2% | -31.9% |
| Current Liabilities | $9.0M | +5.8% | +27.4% |
| Total Liabilities | $9.1M | +5.2% | +12.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.1M | +68.5% | +66.6% |
| Financing Cash Flow | $313K | -88.4% | — |
| -$7.7M |
| -27.0% |
| -27.0% |